Glutathione plays a double role in cancer, one that has puzzled researchers for decades. In healthy cells, it is the body’s most abundant built-in antioxidant, neutralizing toxic compounds and protecting DNA from the kind of damage that can trigger tumors in the first place. Yet once a tumor has formed, cancer cells hijack the same molecule to fuel their own survival, resist chemotherapy, and dodge cell death. This paradox sits at the heart of modern cancer biology and shapes how scientists are developing new treatments.
What Glutathione Does in a Healthy Body
Glutathione is a small molecule made of three amino acids and found in virtually every cell. Its concentration inside cells is remarkably high, generally between 1 and 10 millimolar, making it the most plentiful water-soluble antioxidant you produce on your own.1PubMed Central. Glutathione: A Samsonian life-sustaining small molecule that protects against oxidative stress, ageing and damaging inflammation More than 98 percent of it exists in its active, reduced form, ready to donate electrons to neutralize reactive oxygen species and other damaging molecules.
Your body builds glutathione in two enzymatic steps, with the availability of the amino acid cysteine and the activity of the enzyme glutamate cysteine ligase acting as the main bottlenecks.2PubMed Central. Regulation of glutathione synthesis Beyond mopping up free radicals, glutathione helps detoxify foreign chemicals, supports immune function, and regulates whether a cell lives, divides, or dies.3PubMed Central. Role of Glutathione in Cancer: From Mechanisms to Therapies A family of enzymes called glutathione S-transferases attaches glutathione to harmful compounds, including environmental carcinogens, tagging them for removal. In this way, glutathione is genuinely cancer-preventive: it helps clear the very substances that could otherwise mutate DNA and start a tumor.4PubMed Central. The role of glutathione S-transferases in human disease pathogenesis and their current inhibitors
How Cancer Cells Turn Glutathione to Their Advantage
Cancer cells live in a constant state of oxidative stress. Their rapid growth, altered metabolism, and abnormal signaling all generate far more reactive oxygen species than a normal cell produces. A certain amount of that stress actually helps tumors grow by activating pathways that push cells to divide. Too much, though, would kill them. The solution tumors have evolved is to crank up their antioxidant defenses, and glutathione is at the center of that strategy.5Cancer Cell. Glutathione and Cancer: What Is the Connection?
Many cancers achieve this by overexpressing a transporter called SLC7A11 (also known as xCT), which pulls cystine into the cell. Cystine is quickly converted to cysteine, the rate-limiting building block for making glutathione.6PubMed Central. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy By flooding themselves with raw materials, tumor cells ramp up glutathione production well beyond what healthy tissue needs. The transcription factor NRF2, which normally switches on antioxidant genes in response to stress, is frequently overactivated in tumors. NRF2 drives the expression of genes that both import cystine and assemble glutathione, reinforcing the cancer cell’s shield against oxidative damage.7Exploration of Medicine. Targeting the NRF2 pathway to enhance lipid peroxidation: a novel therapeutic strategy in hepatocellular carcinoma
The result is a kind of metabolic arms race. The tumor needs enough oxidative stress to keep growing but enough glutathione to avoid tipping into cell death. Elevated glutathione levels in tumors have been linked to faster progression and worse treatment responses.3PubMed Central. Role of Glutathione in Cancer: From Mechanisms to Therapies
Drug Resistance and Treatment Failure
One of the most clinically frustrating consequences of high tumor glutathione is drug resistance. Glutathione interferes with chemotherapy in at least two distinct ways. First, it can directly bind to certain drugs and inactivate them before they reach their targets. Second, glutathione fuels the activity of a drug-export pump called MRP (multidrug resistance-associated protein). Depleting glutathione in lab experiments reduced MRP’s ability to push the chemotherapy drug daunorubicin out of cells, suggesting that glutathione is specifically required for this pump to work.8PubMed Central. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein
Research in high-grade serous ovarian cancer has uncovered another layer. A non-coding RNA called H19 was found to regulate several proteins involved in glutathione metabolism. When H19 was knocked down, glutathione levels dropped and cells became markedly more sensitive to cisplatin, one of the most widely used platinum-based chemotherapy drugs.9PubMed Central. The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer These findings paint a consistent picture: tumor cells with higher glutathione are harder to kill with standard treatments.
Radiation therapy faces a similar obstacle. When cells are hit with ionizing radiation, the glutathione and thioredoxin systems kick in to neutralize the resulting free radicals and repair damage. Disrupting either system partially impaired cells’ ability to survive radiation exposure.10PubMed. Spatio-temporal changes in glutathione and thioredoxin redox couples during ionizing radiation-induced oxidative stress regulate tumor radio-resistance In triple-negative breast cancer, cancer stem cells were found to carry particularly high glutathione levels. Depleting that glutathione made those stem cells sensitive to a form of targeted internal radiotherapy that they had previously resisted.11PubMed. Modulation of glutathione promotes apoptosis in triple-negative breast cancer cells
Ferroptosis and the Vulnerability It Creates
The flip side of cancer cells’ glutathione dependence is that it creates a vulnerability. Ferroptosis is a form of cell death driven by the unchecked buildup of damaged fats in cell membranes. The enzyme GPX4 is the last line of defense against this: it uses glutathione to neutralize those dangerous lipid molecules. When glutathione is depleted, GPX4 stops working, lipid damage spirals out of control, and the cell dies.12PubMed Central. Regulation of ferroptotic cancer cell death by GPX4
Researchers have identified two classes of compounds that trigger ferroptosis. One class, including the molecule erastin, blocks cystine import through the xCT transporter, starving the cell of the raw material for glutathione. The other class, such as RSL3, directly inhibits GPX4 without lowering glutathione levels. Both lead to the same outcome: lethal lipid oxidation.13Cell. Regulation of Ferroptosis by Glutathione Peroxidase 4 Because many cancers have become so dependent on glutathione and GPX4 for survival, ferroptosis-inducing strategies are a major area of drug development. The irony is elegant: the same antioxidant addiction that protects tumors from chemotherapy also makes them exquisitely sensitive to having that antioxidant yanked away.
Therapies That Target Glutathione in Tumors
The most studied glutathione-depleting drug is buthionine sulfoximine, usually abbreviated BSO. It blocks the enzyme that catalyzes the first step of glutathione synthesis. In a phase I clinical trial, BSO administered alongside the chemotherapy drug melphalan was shown to reduce glutathione levels in tumors to less than 10 percent of their pre-treatment value.14JNCI: Journal of the National Cancer Institute. Phase I Study of Continuous-Infusion l – S,R -Buthionine Sulfoximine With Intravenous Melphalan Lab studies have shown BSO synergistically enhancing melphalan’s ability to kill myeloma cells, producing two to four additional logs of cell death compared with the drug alone.15Blood Cancer Journal. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma
BSO has also shown promise in breast cancer models. In antihormone-resistant breast cancer cells, combining BSO with estrogen produced a sevenfold increase in programmed cell death, while neither treatment alone had a significant effect on growth. Those results held up in mouse experiments, where BSO shrank tumors either alone or combined with estrogen.16PubMed Central. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
Another approach targets glutamine metabolism upstream of glutathione. A glutaminase inhibitor called CB-839 significantly impaired glutathione production in multiple types of acute myeloid leukemia, leading to a buildup of reactive oxygen species in mitochondria and subsequent cell death.17Clinical Cancer Research. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy Because cancer cells often rely heavily on glutamine to feed both their energy needs and their antioxidant defenses, cutting off this supply line hits them from two directions at once.18PubMed Central. Glutaminase – A potential target for cancer treatment
Cancer Stem Cells and the Tumor Microenvironment
Cancer stem cells are a small subpopulation within tumors thought to drive recurrence after treatment. These cells tend to carry higher glutathione levels than the bulk of the tumor, and that excess appears to be functionally important. In pancreatic cancer, depleting glutathione with drugs undermined cancer stem cells’ ability to self-renew and made them more sensitive to chemotherapy.19PubMed Central. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells Similar findings have emerged in gastric cancer, where blocking glutathione metabolism suppressed the stem-like properties of cells that had been engineered to overexpress a checkpoint molecule called B7-H3.20PubMed Central. B7-H3 confers stemness characteristics to gastric cancer cells by promoting glutathione metabolism through AKT/pAKT/Nrf2 pathway
The broader tumor microenvironment adds another dimension. Tumors are not just collections of cancer cells; they include immune cells, structural support cells, and a soup of metabolites and signaling molecules. Glutathione dynamics influence both cancer stem cells and the T cells that are trying to attack the tumor. In the harsh, acidic, oxygen-starved conditions inside a tumor, glutathione availability can tip the balance between immune cells that remain functional and those that become exhausted.21PubMed Central. Glutathione Dynamics in the Tumor Microenvironment: A Potential Target of Cancer Stem Cells and T Cells This makes glutathione manipulation a potential complement to immunotherapy, though this idea remains in early research stages.
Why Antioxidant Supplements Can Backfire
If glutathione helps cancer cells survive, what happens when you boost antioxidant levels with supplements? The evidence is worrying. In mice genetically predisposed to lung cancer, long-term supplementation with the antioxidants N-acetylcysteine (NAC, a direct precursor to glutathione) and vitamin E promoted cancer metastasis. The mechanism involved stabilization of a protein called BACH1, which shifted cancer cell metabolism in ways that enhanced their ability to spread.22Cell. Antioxidants Accelerate Lung Cancer Metastasis by Stabilizing BACH1 and Promoting Glycolysis
In a separate study using aging mice with chronic lung oxidative stress, NAC treatment did protect against emphysema, which is what you would expect from a good antioxidant. But it simultaneously induced lung adenocarcinoma in half of the genetically susceptible animals and 10 percent of otherwise normal aged mice.23PubMed Central. The antioxidant N-acetylcysteine protects from lung emphysema but induces lung adenocarcinoma in mice These are animal studies, and translating them directly to human supplement use requires caution. But they reinforce a broader theme from large human trials of antioxidant vitamins: in people who already have cancer or are at high risk, supplemental antioxidants do not reliably prevent disease and may actively make things worse.
The reasoning is straightforward once you understand the paradox. Healthy cells have low oxidative stress, so the marginal benefit of extra antioxidant is small. Cancer cells, running on high oxidative stress by design, gain much more from an antioxidant boost. Supplementing effectively provides more cover for the very cells you want to kill.
Glutathione Infusions During Chemotherapy
Confusingly, some clinical trials have tested giving glutathione to cancer patients, not to fight the tumor but to protect healthy tissue from chemotherapy side effects. In a randomized trial of women with ovarian cancer receiving cisplatin, those who got intravenous glutathione alongside their chemo had significantly better quality of life: less nausea, less hair loss, less nerve damage, and less depression. A higher proportion of them completed all six cycles of treatment compared with controls.24PubMed. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial
A separate double-blind trial in advanced gastric cancer found striking neuroprotection. After 15 weeks of cisplatin-based treatment, only four of 24 patients in the glutathione group showed signs of nerve damage versus 16 of 18 in the placebo group. Nerve conduction studies confirmed the difference. The researchers concluded that glutathione did not appear to reduce the anticancer activity of the chemotherapy.25PubMed. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial
However, results have not been uniformly positive. A larger phase III trial testing glutathione for preventing nerve damage from paclitaxel and carboplatin in various cancers found no significant benefit. In patients receiving weekly paclitaxel, the placebo group actually did better on measures of acute pain.26PubMed Central. NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study So the evidence is mixed and probably depends on the specific drug regimen. The older cisplatin trials were promising, but the field has not reached a consensus that glutathione infusions should be standard practice during chemotherapy.
The tension is real and somewhat uncomfortable: researchers are simultaneously trying to deplete glutathione in tumors to make treatments more effective and considering supplementing it in patients to reduce treatment toxicity. These are not necessarily contradictory goals, since the infused glutathione may preferentially protect normal tissue while not reaching sufficient concentrations inside the tumor to matter. But it underscores how context-dependent glutathione’s effects are.
Imaging Tumors by Tracking Glutathione
Because glutathione is consistently elevated in tumor cells, researchers have explored using it as a signal for detection and monitoring. One approach uses manganese dioxide nanotubes as a photoacoustic imaging probe. When these nanotubes encounter the high glutathione concentrations inside a tumor, they react in a way that switches on a detectable signal, offering a potential route to high-resolution, deep-tissue tumor imaging.27PubMed Central. Switchable Photoacoustic Imaging of Glutathione Using MnO2 Nanotubes for Cancer Diagnosis
On the PET scanning side, experimental tracers are being developed to image the xCT transporter that imports cystine for glutathione production. One such tracer, 18F-FASu, could potentially identify tumors that are heavily dependent on cystine uptake, helping doctors select patients most likely to respond to therapies targeting that transporter.28PubMed Central. Functional Imaging of Oxidative Stress with a Novel PET Imaging Agent, 18F-5-Fluoro-l-Aminosuberic Acid Another experimental PET tracer built on a fluorine-18-labeled glutathione conjugate successfully identified brain tumors in rats, with the signal coinciding with tumor locations confirmed by MRI.29PLOS ONE. 18F-Glutathione Conjugate as a PET Tracer for Imaging Tumors that Overexpress L-PGDS Enzyme None of these imaging tools are in routine clinical use yet, but they illustrate how glutathione’s role in cancer could eventually be exploited not just for treatment but for smarter diagnosis and treatment planning.
What Fasting and Diet Have to Do With It
Fasting and fasting-mimicking diets have attracted attention as possible ways to create metabolic stress that selectively harms cancer cells. The underlying idea connects to glutathione, though indirectly. Normal cells, when deprived of nutrients, dial down their growth signals and hunker into a protective state. Cancer cells, locked into growth mode by their mutations, cannot do this as effectively. Early-phase clinical trials suggest that fasting around chemotherapy may be safe and feasible, with some evidence of improved treatment tolerance, though the data remain preliminary.30Dove Press / International Journal of General Medicine. Fasting and Fasting-Mimicking Diets as Adjunctive Strategies in Cancer Therapy: Mechanisms, Evidence, and Clinical Implications Nutrient deprivation can reduce the raw materials available for glutathione synthesis, which may contribute to the selective vulnerability of cancer cells during fasting periods. This is still an area where the science is outrunning the clinical evidence, and no oncology guidelines currently recommend fasting as part of standard cancer care.